Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners restated a “buy” rating on shares of Evogene in a report on Friday, March 7th.

Evogene Stock Down 6.9 %

EVGN opened at $1.15 on Thursday. The business’s fifty day simple moving average is $1.43 and its 200 day simple moving average is $1.79. Evogene has a 52 week low of $1.17 and a 52 week high of $9.00. The stock has a market cap of $6.14 million, a PE ratio of -0.26 and a beta of 1.28.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. The company had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $3.63 million. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. During the same period last year, the firm posted ($1.30) EPS.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC purchased a new position in Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned 0.30% of Evogene at the end of the most recent reporting period. 10.40% of the stock is currently owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.